Literature DB >> 1315896

Agonist and antagonist activities of ligands derived from naltrexone and oxymorphone.

A E Takemori1, M Sultana, H Nagase, P S Portoghese.   

Abstract

The pharmacological profile of naltrindole (NTI) and three of its analogues, N-methyl-NTI (N-Me-NTI), oxymorphindole (OMI) and naltriben (NTB) were studied in antinociceptive assays. The compounds were found to have agonist activities that appear to be mediated mainly by kappa opioid receptors because norbinaltorphimine (nor-BNI), the selective kappa opioid receptor antagonist inhibited their effects significantly. All of the compounds, behaved as antagonists at doses that were lower than those that produced agonist effects and they possessed a profile that was very selective for inhibiting the antinociceptive activities of delta opioid receptor agonists. Differential antagonism by NTB of the activities of DSLET and DPDPE was demonstrated.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1315896     DOI: 10.1016/0024-3205(92)90138-f

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  10 in total

1.  5'-halogenated analogs of oxymorphindole.

Authors:  Matthew D Metcalf; Andrew Coop
Journal:  Bioorg Med Chem Lett       Date:  2007-08-23       Impact factor: 2.823

2.  Activation of TRPM7 channels by small molecules under physiological conditions.

Authors:  T Hofmann; S Schäfer; M Linseisen; L Sytik; T Gudermann; V Chubanov
Journal:  Pflugers Arch       Date:  2014-03-15       Impact factor: 3.657

3.  Delta-opioid receptor-mediated modulation of excitability of individual hippocampal neurons: mechanisms involved.

Authors:  Lucia Moravcikova; Roman Moravcik; Daniela Jezova; Lubica Lacinova; Eliyahu Dremencov
Journal:  Pharmacol Rep       Date:  2020-11-08       Impact factor: 3.024

4.  Sensitivity to μ-opioid receptor-mediated anti-nociception is determined by cross-regulation between μ- and δ-opioid receptors at supraspinal level.

Authors:  J J Ballesta; J Cremades; M Rodríguez-Muñoz; J Garzón; C C Faura
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

5.  Central Nervous System Distribution of an Opioid Agonist Combination with Synergistic Activity.

Authors:  Jessica I Griffith; Minjee Kim; Daniel J Bruce; Cristina D Peterson; Kelley F Kitto; Afroz S Mohammad; Sneha Rathi; Carolyn A Fairbanks; George L Wilcox; William F Elmquist
Journal:  J Pharmacol Exp Ther       Date:  2021-10-18       Impact factor: 4.030

6.  Delta-opioid receptor antagonists prevent sensitization to the conditioned rewarding effects of morphine.

Authors:  Toni S Shippenberg; Vladimir I Chefer; Alexis C Thompson
Journal:  Biol Psychiatry       Date:  2008-10-31       Impact factor: 13.382

7.  Delta opioidmimetic antagonists: prototypes for designing a new generation of ultraselective opioid peptides.

Authors:  S Salvadori; M Attila; G Balboni; C Bianchi; S D Bryant; O Crescenzi; R Guerrini; D Picone; T Tancredi; P A Temussi
Journal:  Mol Med       Date:  1995-09       Impact factor: 6.354

8.  A uniform molecular model of delta opioid agonist and antagonist pharmacophore conformations.

Authors:  W Brandt
Journal:  J Comput Aided Mol Des       Date:  1998-11       Impact factor: 3.686

Review 9.  Targeting endogenous mu- and delta-opioid receptor systems for the treatment of drug addiction.

Authors:  T S Shippenberg; A LeFevour; V I Chefer
Journal:  CNS Neurol Disord Drug Targets       Date:  2008-11       Impact factor: 4.388

10.  Agonist-induced phosphorylation bar code and differential post-activation signaling of the delta opioid receptor revealed by phosphosite-specific antibodies.

Authors:  Anika Mann; Sophia Liebetrau; Marie Klima; Pooja Dasgupta; Dominique Massotte; Stefan Schulz
Journal:  Sci Rep       Date:  2020-05-22       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.